Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
ABVC's pipeline includes oncology therapeutics derived from plant compounds and cancer-focused programs.
|
$62.86M |
$2.68
+4.28%
|
|
LINK
Interlink Electronics, Inc.
Medical devices & biometrics is a target end-market for Interlink’s sensor and printed electronics solutions.
|
$61.40M |
$4.20
-0.71%
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$60.69M |
$1.01
+8.63%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$60.65M |
$9.94
+2.90%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$60.23M |
$5.09
+4.30%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$59.39M |
$0.60
+6.85%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$59.00M |
$1.81
+0.56%
|
|
SOTK
Sono-Tek Corporation
Medical device coatings are a key application (balloon catheters, stents), linking Sono-Tek to Medical Devices & Equipment.
|
$58.35M |
$3.82
-2.55%
|
|
BDSX
Biodesix, Inc.
Biodesix's Nodify and VeriStrat are blood-based diagnostic tests, i.e., liquid biopsy products.
|
$57.70M |
$7.63
-1.42%
|
|
NEPH
Nephros, Inc.
FDA-cleared medical devices (infection-control filters) used in hospitals and dialysis centers.
|
$57.35M |
$5.50
-3.25%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$57.29M |
$4.14
+4.81%
|
|
BLGO
BioLargo, Inc.
Clyra Medical infection control products classify BioLargo under Medical Devices & Biometrics.
|
$56.59M |
$0.15
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$56.39M |
$1.69
+5.62%
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$55.20M |
$2.10
+1.20%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$54.10M |
$4.89
+2.19%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$52.85M |
$1.99
+0.76%
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$51.84M |
$5.54
-3.32%
|
|
AAME
Atlantic American Corporation
Bankers Fidelity provides health insurance products (Medicare supplement and group health), expanding L&H offerings.
|
$51.20M |
$2.51
+0.40%
|
|
ANL
Adlai Nortye Ltd.
The company’s pipeline includes oral small-molecule therapeutics (e.g., AN4005, AN9025), aligning with the Oral Small Molecule Therapeutics category.
|
$50.87M |
$1.37
-1.44%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$50.48M |
$10.98
+0.69%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$50.36M |
$7.94
-0.25%
|
|
ACET
Adicet Bio, Inc.
Directly develops allogeneic cell therapies (gamma delta T cells) for autoimmune diseases and cancer as its primary product platform.
|
$50.04M |
$0.60
+0.53%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$49.95M |
$0.85
+2.93%
|
|
CTSO
Cytosorbents Corporation
CytoSorbents' core offering is the CytoSorb blood purification device used in ICU and cardiac surgery to remove inflammatory mediators and toxins.
|
$49.64M |
$0.79
-5.59%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$48.36M |
$0.76
+4.04%
|
|
AIRG
Airgain, Inc.
AT-Flight asset tracker and its healthcare usage aligns Airgain with Medical Devices & Biometrics as a healthcare-oriented device offering.
|
$48.33M |
$4.13
+0.73%
|
|
ZYXI
Zynex, Inc.
Directly manufactures medical devices and biometrics used for patient monitoring and non-opioid pain management.
|
$48.17M |
$1.58
+114.27%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$48.13M |
$5.54
+1.74%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$48.09M |
$0.66
+8.23%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$46.65M |
$0.55
+3.98%
|
|
NRXP
NRx Pharmaceuticals, Inc.
NRx's pipeline centers on neuropsychiatric drug development (NRX-100, NRX-101) targeting suicidal depression and bipolar depression.
|
$46.11M |
$2.35
+7.80%
|
|
COSG
Cosmos Group Holdings Inc.
Patent filings target glioma and hematologic malignancies, indicating focus on oncology biotech.
|
$45.86M |
$0.01
|
Showing page 28 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
